ArticleBMC women's health2025
Prognostic factors of progesterone resistance in symptomatic adenomyosis: impact of lesion localization on treatment outcome of levonorgestrel intrauterine system.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pretreatment MRI parameters as predictive biomarkers for short-term clinical response to dienogest in adenomyosis: a retrospective cohort study.Abdominal radiology (New York) · 2026Article
- Combined magnetic resonance imaging with serum CA125 for dysmenorrhea in adenomyosis.Scientific reports · 2025Article
- Phenotypic heterogeneity in adenomyosis: internal and external subtypes.Archives of gynecology and obstetrics · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Adenomyosis often causes dysmenorrhea in women of reproductive age. Progestins such as levonorgestrel intrauterine system (LNG-IUS) are often used for treatment, but some patients experience progesterone resistance, showing poor treatment response. However, the clinical characteristics of progesterone-resistant and progesterone-sensitive patients with symptomatic adenomyosis remain unclear. We analyzed data of 69 patients with adenomyosis treated with LNG-IUS. Dysmenorrhea was quantified using linear visual analog scale (VAS) scoring, and progesterone resistance was interpreted as continued dysmenorrhea during LNG-IUS treatment. The rate of change in VAS scores of dysmenorrhea was calculated: patients with the bottom 25% improvement were defined as progesterone-resistant group, and those with the top 25% improvement as progesterone-sensitive group. The localization of adenomyosis lesions was evaluated by magnetic resonance imaging (MRI) and classified as advanced (localized in all layers of the myometrium), extrinsic (localized on the uterine serosa side), and intrinsic (localized on the endometrial side) subtypes. Progesterone-resistant group had a significantly lower incidence of intrinsic adenomyosis (7.7% vs. 69.2%, p = 0.004) and a tendency toward a higher incidence of advanced adenomyosis (61.5% vs. 23.1%, p = 0.111) compared with progesterone-sensitive group. Progesterone-sensitive group showed significant improvement of dysmenorrhea 1 month after starting LNG-IUS treatment (p < 0.001). These findings indicate that the responsiveness to LNG-IUS treatment can be determined 1 month after starting the treatment and that intrinsic adenomyosis is a favorable prognostic factor for progestin treatment with LNG-IUS, while advanced and extrinsic adenomyosis are predictors for progesterone resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.